Limits...
An In silico Chimeric Vaccine Targeting Breast Cancer Containing Inherent Adjuvant.

Imani Fooladi AA, Mahmoodzadeh Hosseini H, Amani J - Iran J Cancer Prev (2015)

Bottom Line: We hypothesized the extracellular domain of receptor tyrosine kinase like orphan receptor 1 (ROR-1) along with a super antigen such as staphylococcal enterotoxin B could be a potent vaccine for drug resistant breast cancer.Here, we assessed the findings of bioinformatics analysis to identify the antitumor immune properties of this chimeric construct.Our result suggested that chimeric model is capable to be a stimulant of both T-cell and B- cell mediated immune responses with an acceptable accessibility and solubility but without any allergenicity.

View Article: PubMed Central - PubMed

Affiliation: Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.

ABSTRACT

Background: Today, Lack of efficient therapeutic strategy for breast cancer (the most common cause of death in women) is one of the momentous problematic topics for all health care committees. Designing new specific vaccine, based on antigens located on the surface of cancer cells can be useful. Over expression of ROR1, lacked of HER2/neu, and hormone receptors on cell surface in the breast cancer, introduce this protein as an appropriate candidate for designing cancer vaccine.

Objectives: We hypothesized the extracellular domain of receptor tyrosine kinase like orphan receptor 1 (ROR-1) along with a super antigen such as staphylococcal enterotoxin B could be a potent vaccine for drug resistant breast cancer.

Materials and methods: Here, we assessed the findings of bioinformatics analysis to identify the antitumor immune properties of this chimeric construct. In addition, the stability, physic-chemical properties and allergic potency of designed fusion protein were investigated by valid bioinformatics software.

Results: Our result suggested that chimeric model is capable to be a stimulant of both T-cell and B- cell mediated immune responses with an acceptable accessibility and solubility but without any allergenicity.

Conclusions: The ROR-1 with an enterotoxin B could be a potent vaccine for breast cancer.

No MeSH data available.


Related in: MedlinePlus

Schematic representation of ROR1-SEB constructs containing two extracellular domains of ROR1 (Ig-like C2 type and Frizzled domain) and the whole sequence of SEB fusing together with a hydrophobic linker
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4581362&req=5

A2326FIG1: Schematic representation of ROR1-SEB constructs containing two extracellular domains of ROR1 (Ig-like C2 type and Frizzled domain) and the whole sequence of SEB fusing together with a hydrophobic linker

Mentions: The extracellular part of ROR1 was selected for designing the N-terminal of chimeric because of its accessibility to antigen presenting cells. This part has consisted of the Frizzled domain, which involves in proliferation, cell polarity and cell developing, and Ig-like C2 type domain, which participates in cell-cell recognition and immune system stimulation. Full- length of SEB was conjugated with GSGGSGGSGGSG linker to ROR1 and formed C-terminal of the described construct. Figure 1 depicts the schematic diagram of chimeric construct using DOG 1.0 software (23). Based on VaxiJen outcomes, the antigenicity index of ROR1 fragment alone, SEB fragment, linker and the combination of all three mentioned parts were 0.6488, 0.5618, 4.9849 and 0.5994.


An In silico Chimeric Vaccine Targeting Breast Cancer Containing Inherent Adjuvant.

Imani Fooladi AA, Mahmoodzadeh Hosseini H, Amani J - Iran J Cancer Prev (2015)

Schematic representation of ROR1-SEB constructs containing two extracellular domains of ROR1 (Ig-like C2 type and Frizzled domain) and the whole sequence of SEB fusing together with a hydrophobic linker
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4581362&req=5

A2326FIG1: Schematic representation of ROR1-SEB constructs containing two extracellular domains of ROR1 (Ig-like C2 type and Frizzled domain) and the whole sequence of SEB fusing together with a hydrophobic linker
Mentions: The extracellular part of ROR1 was selected for designing the N-terminal of chimeric because of its accessibility to antigen presenting cells. This part has consisted of the Frizzled domain, which involves in proliferation, cell polarity and cell developing, and Ig-like C2 type domain, which participates in cell-cell recognition and immune system stimulation. Full- length of SEB was conjugated with GSGGSGGSGGSG linker to ROR1 and formed C-terminal of the described construct. Figure 1 depicts the schematic diagram of chimeric construct using DOG 1.0 software (23). Based on VaxiJen outcomes, the antigenicity index of ROR1 fragment alone, SEB fragment, linker and the combination of all three mentioned parts were 0.6488, 0.5618, 4.9849 and 0.5994.

Bottom Line: We hypothesized the extracellular domain of receptor tyrosine kinase like orphan receptor 1 (ROR-1) along with a super antigen such as staphylococcal enterotoxin B could be a potent vaccine for drug resistant breast cancer.Here, we assessed the findings of bioinformatics analysis to identify the antitumor immune properties of this chimeric construct.Our result suggested that chimeric model is capable to be a stimulant of both T-cell and B- cell mediated immune responses with an acceptable accessibility and solubility but without any allergenicity.

View Article: PubMed Central - PubMed

Affiliation: Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.

ABSTRACT

Background: Today, Lack of efficient therapeutic strategy for breast cancer (the most common cause of death in women) is one of the momentous problematic topics for all health care committees. Designing new specific vaccine, based on antigens located on the surface of cancer cells can be useful. Over expression of ROR1, lacked of HER2/neu, and hormone receptors on cell surface in the breast cancer, introduce this protein as an appropriate candidate for designing cancer vaccine.

Objectives: We hypothesized the extracellular domain of receptor tyrosine kinase like orphan receptor 1 (ROR-1) along with a super antigen such as staphylococcal enterotoxin B could be a potent vaccine for drug resistant breast cancer.

Materials and methods: Here, we assessed the findings of bioinformatics analysis to identify the antitumor immune properties of this chimeric construct. In addition, the stability, physic-chemical properties and allergic potency of designed fusion protein were investigated by valid bioinformatics software.

Results: Our result suggested that chimeric model is capable to be a stimulant of both T-cell and B- cell mediated immune responses with an acceptable accessibility and solubility but without any allergenicity.

Conclusions: The ROR-1 with an enterotoxin B could be a potent vaccine for breast cancer.

No MeSH data available.


Related in: MedlinePlus